NasdaqCM - Delayed Quote USD

TRACON Pharmaceuticals, Inc. (TCON)

1.8100 +0.0200 (+1.12%)
At close: 4:00 PM EDT
1.8101 +0.00 (+0.01%)
After hours: 4:02 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for TCON

Recent News: TCON

View More
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
InvestorPlace 16 days ago
TRACON Pharmaceuticals Announces Reverse Stock Split

TRACON Pharmaceuticals Announces Reverse Stock Split
GlobeNewswire 18 days ago
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
GlobeNewswire 23 days ago
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
Insider Monkey last month
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire last month
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024

TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
GlobeNewswire last month
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
GlobeNewswire 4 months ago

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
InvestorPlace 5 months ago
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment

TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
GlobeNewswire 5 months ago
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q3 2023 Earnings Call Transcript
Insider Monkey 5 months ago
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 5 months ago
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023

TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
GlobeNewswire 5 months ago
View More

Related Tickers

NRXP NRx Pharmaceuticals, Inc.
3.5400
+12.74%
 
EYEN Eyenovia, Inc.
0.6282
-11.68%
 
ASLN ASLAN Pharmaceuticals Limited
0.4153
-7.30%
 
GLMD Galmed Pharmaceuticals Ltd.
0.3916
+0.90%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
2.9900
+0.34%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
CNTB Connect Biopharma Holdings Limited
1.3400
-0.74%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
JAGX Jaguar Health, Inc.
0.1800
+5.88%
 
NKGN NKGen Biotech, Inc.
1.6100
-18.69%